Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk
of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor
inhibitor in patients with coronary artery disease (CAD). However, despite its benefits, many
patients still experience recurrent atherothrombotic events. The proposed study will test the
central hypothesis that in DM patients the presence of CKD reduces clopidogrel-mediated P2Y12
inhibitory effects through synergistic mechanisms, which include upregulation of the P2Y12
signaling pathway and impaired clopidogrel metabolism.